Picture loading failed.

Pre-Made Elgemtumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Elgemtumab, also known as LJM716, is a high- affinity IgG1κ type monoclonal antibodies selected from a Human Combinatorial Antibody Library (HuCAL). It can specifically bind to ERBB3 to neutralize multiple modes of ERBB3 activation.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-170-1mg 1mg 3090
GMP-Bios-ab-170-10mg 10mg Inquiry
GMP-Bios-ab-170-100mg 100mg Inquiry
GMP-Bios-ab-170-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Elgemtumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody
INN Name Elgemtumab
TargetErbb-3
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4p59:HL
Year Proposed2014
Year Recommended2015
CompaniesMorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours
Development TechMedarex HuMAb Mouse